Although increased intratumoral expression of activated STAT6 based on histopathologic analysis is associated with poor clinical outcomes in PCNSL (34), quantification of STAT6 expression requires an invasive procedure and is not widely available clinically. This evidence concerns the gene STAT6 and primary central nervous system lymphoma.